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Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM)
because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver
disease (NAFLD) in patients with T2DM, we determined the impact of 6 months’ GLP-1 RA therapy on intrahepatic lipid (IHL)
in obese, T2DM patients with hepatic steatosis, and evaluated the inter-relationship between changes in IHL with those in
glycosylated haemoglobin (HbA1c), body weight, and volume of abdominal visceral and subcutaneous adipose tissue (VAT
and SAT). We prospectively studied 25 (12 male) patients, age 50610 years, BMI 38.465.6 kg/m2 (mean 6 SD) with baseline
IHL of 28.2% (16.5 to 43.1%) and HbA1c of 9.6% (7.9 to 10.7%) (median and interquartile range). Patients treated with
metformin and sulphonylureas/DPP-IV inhibitors were given 6 months GLP-1 RA (exenatide, n = 19; liraglutide, n = 6). IHL
was quantified by liver proton magnetic resonance spectroscopy (1H MRS) and VAT and SAT by whole body magnetic
resonance imaging (MRI). Treatment was associated with mean weight loss of 5.0 kg (95% CI 3.5,6.5 kg), mean HbA1c
reduction of 1?6% (17 mmol/mol) (0?8,2?4%) and a 42% relative reduction in IHL (259.3, 216.5%). The relative reduction in
IHL correlated with that in HbA1c (r= 0.49; p = 0.01) but was not significantly correlated with that in total body weight, VAT
or SAT. The greatest IHL reduction occurred in individuals with highest pre-treatment levels. Mechanistic studies are needed
to determine potential direct effects of GLP-1 RA on human liver lipid metabolism.
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Introduction
The glucagon-like peptide-1 (GLP-1) receptor agonists are used
as blood glucose-lowering treatments of obese patients with type 2
diabetes mellitus (T2DM). GLP-1 acts through several distinct
mechanisms including stimulation of glucose-dependent insulin
secretion, inhibition of glucagon secretion, delay of gastric
emptying and promotion of weight loss through central inhibition
of appetite [1]. In patients treated with GLP-1 receptor agonists
(GLP-1 RA), the weight loss is predominantly associated with a
reduction in adipose tissue [2] although the inter-relationships
between the relative amounts of visceral, subcutaneous and
hepatic fat loss remain unknown.
NAFLD describes a disease spectrum with excessive deposition
of fat within the liver (hepatic steatosis), which may be associated
with inflammation, cell death, and fibrosis (non-alcoholic steato-
hepatitis, NASH), ultimately progressing to cirrhosis [3]. NAFLD
has a high prevalence in patients with type 2 diabetes, diagnosed
variously on the basis of abnormal liver biochemistry, ultrasonog-
raphy [4], proton magnetic resonance spectroscopy (1H MRS) or
liver biopsy [5–7]. For example, the Edinburgh Diabetes Study,
which carefully excluded secondary causes of steatosis, demon-
strated hepatic steatosis in 57% of type 2 diabetes patients by
ultrasonography, with NAFLD-related steatosis in 43% [4]. This
high prevalence is not simply explained by the high incidence of
obesity in type 2 diabetes, as liver fat is increased in patients with
type 2 diabetes compared with age- and BMI-matched healthy
controls [5,8–11] but is important for several reasons. Epidemi-
ological studies highlight an increased prevalence of chronic liver
disease and hepatocellular carcinoma in patients with type 2
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diabetes [10,12]. Furthermore, NAFLD is associated with a higher
prevalence of cardiovascular disease and a greater burden of
diabetic complications in patients with type 2 diabetes [13–16].
The impact of reducing liver fat by lifestyle or pharmacological
intervention on the natural history or the frequency of these long-
term complications is unknown.
Current treatment of NAFLD is aimed at weight loss through
lifestyle interventions involving diet and exercise [17–20]. Petersen
et al. demonstrated that modest weight reduction (,8 kg) in
patients with type 2 diabetes substantially reduced hepatic steatosis
(by ,80%) and concomitantly improved hepatic insulin resistance
[19,21]. Treatment with metformin or glitazone (either rosiglita-
zone or pioglitazone) may also ameliorate NAFLD, with metabolic
and histological improvement, predominantly through reduced
steatosis and inflammation, with little effect on fibrosis [22–25]. As
for GLP-1 RAs, Buse et al demonstrated that 2 years exenatide
therapy was associated with significant improvement in abnormal
liver transaminases, biomarkers of hepatocyte injury most
commonly reflecting NAFLD [26]. Tushuizen directly examined
the effect of exenatide therapy on hepatic steatosis measured non-
invasively by 1H MRS, showing that 44 weeks of treatment was
associated with a reduction in liver fat from 16.0 to 5?4% [27].
This is supported by a recent case series of 8 patients with type 2
diabetes and biopsy-proven NAFLD who underwent liver biopsies
before and after 28 weeks of exenatide therapy, in 3 of whom liver
histology improved [28].
The present study was undertaken to define the inter-
relationship between the reduction in intrahepatic lipid (IHL)
and changes in glycaemic control and body composition (body
weight, VAT and SAT) in patients with type 2 diabetes and
hepatic steatosis receiving GLP-1 receptor agonists, to determine
what factors are associated with the reduction in liver fat observed
with these drugs.
Research Design and Methods
Inclusion and Exclusion Criteria
Patients were prospectively recruited from four specialist
diabetes outpatient clinics. The inclusion criteria were: i) known
type 2 diabetes with ii) obesity (BMI.35 kg/m2), and iii) at least 3
months treatment on a stable dose regime of maximal doses of
metformin, with either sulphonylureas or DPP-IV inhibitors.
Exclusion criteria were: i) treatment within the last 3 months with
pioglitazone, orlistat, insulin, any other drugs associated with
hepatic steatosis (including glucocorticoids, tamoxifen, amioda-
rone or methotrexate), ii) weekly alcohol intake .14 units for
women or .21 units for men, iii) any history of liver disease
including metabolic or auto-immune liver disease or viral hepatitis.
Patients who fulfilled these criteria were screened for hepatic
steatosis using 1H MRS and those with hepatic steatosis
(IHL.5.5%) continued in the study. A pre-existing clinical
diagnosis of NAFLD was not deemed necessary for inclusion
due to the high prevalence of undiagnosed NAFLD in T2DM.
The Liverpool Research Ethics Committee approved the study
protocol and all participants gave their written informed consent.
25 of the 31 eligible patients who were underwent baseline
scanning completed the study. The six dropouts initiated
treatment after baseline assessments but one declined follow-up,
two developed unrelated medical issues requiring withdrawal from
study and three discontinued GLP-1 treatment due to gastroin-
testinal side effects.
Drug history of patients
All patients were treated with the maximal tolerated dose of
metformin for a minimum of 3 months before recruitment and
they remained on the same mean metformin dose throughout (4
patients required a minor dosage adjustment). 16 patients were
treated with sulphonylurea (SU) therapy with gliclazide (n = 12;
continued in all patients with adjustment of dose in 4) or with the
DPP-IV inhibitor, sitagliptin (n = 4; discontinued in all). No
patients had received pioglitazone within the 3 months prior to
recruitment.
Initiation of GLP-1 RA Therapy
Participants were initiated on GLP-1 RA therapy in accordance
with UK National Institute for Clinical Excellence guidelines [29]
which mandate that only selected patients are eligible for GLP-1
RA therapy: those patients with a BMI.35 kg/m2, and those with
a BMI,35 kg/m2 in whom there is a co-morbid condition for
which weight loss would be desirable, e.g. obstructive sleep
apnoea, NAFLD or polycystic ovary syndrome. The choice of
GLP-1 RA was in accordance with NICE recommendations at the
time of drug initiation (exenatide was approved and available for
use in UK by NICE before liraglutide was approved). Of the
patients who completed the 6-month study period, 19 were treated
with exenatide and 6 with liraglutide. Exenatide was initiated at
5 mcg twice daily, titrated to 10 mcg twice daily after one month;
liraglutide was initiated at 0?6 mg once daily, titrated to 1?2 mg
once daily. All patients remained under the supervision of a
diabetes specialist team throughout the study.
Lifestyle Variables
Patients were not provided with specific guidance on modifi-
cation of diet or physical activity. 18 patients were abstinent from
alcohol throughout; mean weekly consumption in the remaining
patients was 365 units pre-treatment and 265 units post-
treatment. 24 patients were non-smokers throughout the study.
All measurements were made at baseline, prior to initiation of the
drug, and after 6 months of therapy.
Determination of Body Composition
A single observer (AI), who was not involved in the clinical care
of the patients, made all of the measurements. Body weight was
measured with a Tanita bioimpedance analyser, wearing light
clothing (Tanita BC420, Dolby Medical, Stirling, UK). Height was
measured using a stadiometer to the nearest 0.5 cm (Seca,
Birmingham, UK). Waist circumference was taken at the mid-
point between the anterior superior iliac spine and the lower edge
of the rib cage.
Serum Biochemistry and Total Adiponectin
Concentration
Serum glucose, lipid profiles and liver biochemistry were
determined by using the Olympus AU2700 analyser (Beckman
Coulter (UK) Ltd) with standard proprietary reagents. Total serum
adiponectin levels were determined using a quantitative sandwich
ELISA kit (R & D Systems Europe Ltd, Oxon, UK). Each sample
was run in triplicates and the mean value was obtained by
calculation using the standard curve method. Paired pre- and post-
treatment samples were run on the same ELISA plate to minimise
plate-related assay variation. The percentage inter-assay variation
was between 0.4–9.8%.
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Magnetic Resonance Methods
Participants underwent MR scanning in a 1.5T Siemens
Symphony scanner (Siemens Medical Solutions, Erlangen, Ger-
many) at a single site, the University of Liverpool Magnetic
Resonance and Image Analysis Research Centre, as previously
described [30] A single experienced radiographer (VLA) per-
formed all scans.
Volumetric Analysis of Subcutaneous and Visceral Fat
Abdominal subcutaneous adipose tissue (abdominal SAT) and
abdominal visceral adipose tissue (abdominal VAT) were calcu-
lated from whole body axial T1-weighted fast spin echo scans
(axial scans, 10 mm slice thickness followed by a 10 mm gap using
the integral body coil). All images were anonymised and blinded to
time-point, but not to subject (to facilitate matching anatomical
landmarks), and analysed by Vardis (Vardis Group Inc., London,
UK) using SliceOMatic (Tomovision, Montreal, Canada).
Proton Magnetic Resonance Spectroscopy
(1H MRS): In liver, NAFLD was defined as intrahepatocellular
lipid (IHL) .5?5% measured by 1H MRS [7] Three voxels of
interest were identified in the liver standard sites avoiding ducts
and vasculature. In skeletal muscle, 1H MRS was used to measure
intramyocellular lipid (IMCL), using a single voxel in each of the
tibialis anterior (TA) and soleus (Sol) muscles, avoiding bone, fascia
and the neurovascular bundle. Single voxel spectroscopy was
conducted at each of these five sites. Voxel size was
20620620 mm, TE 135 ms, TR 1500 ms, with 64 acquisitions.
Where the musculature was too small to allow placement of a
20 mm voxel, a 15615620 mm voxel was placed and the number
of acquisitions increased to 200 to maintain signal-to-noise ratio.
In both liver and muscle, voxel placement in post-treatment
studies was guided by reference to the pre-treatment images. 1H
MR spectra were quantified using the AMARES algorithm in the
software package jMRUI-3.0. As previously described, IHCL is
expressed as percentage of CH2 lipid signal amplitude relative to
water signal amplitude after correcting for T1 and T2, and IMCL
is expressed as CH2 lipid amplitude relative to total creatine
amplitude after correcting for T1 and T2 [31]). Fat quantification
by 1H MRS has been validated against gold standard biochemical
measurements [32].
Reproducibility of MRI and MRS Analysis
Volumetric analysis of adipose tissue content: the mean coefficient of
variations (CoV) were determined as total body fat, 1–2%; total
subcutaneous fat, 3–4%; abdominal subcutaneous fat, 1–3%;
visceral fat, 6–8%.
Quantification of Liver Fat (IHCL CH2/Water)
The mean inter-examination CoV for using this protocol is 7%
(range 4–12%) and the mean intra-examination CoV is 6% [31].
Statistical Analysis
Statistical analyses were performed using Stata/IC 12.0
software [StataCorp LP, College Station, TX, USA]. Demo-
graphic data are presented as mean 6 standard deviation except
where distributions were non-normal, in which case median and
interquartile range (IQR) are presented. Paired t-tests were used to
assess the absolute differences between individuals pre- and post-
treatment (pre – post) and are presented as mean differences with
95% confidence intervals. In some cases log transformation of the
data was necessary to achieve normality and where unsuccessful
the Wilcoxon matched-pairs test was used. Relative changes are
presented as median and interquartile range. Subgroups were
compared using unpaired t-tests. Correlation was assessed using
the Pearson correlation coefficient (r) where the relevant assump-
tions were met; otherwise the Spearman rank correlation
coefficient (r) was used. Linear regression was used to assess the
linear relationships between IHCL changes and changes in other
variables independently. No corrections have been made for
multiple comparisons.
Results
Baseline Characteristics (Table 1)
25 patients (12 male), age 50610 years, BMI 38.465.6 kg/m2
with a duration of T2DM of 664 years (means 6 SD)
participated. Baseline median liver fat was 28.2% (IQR 16.5,
43.1).
Correlation of Baseline Characteristics with Intrahepatic
Lipid
Biochemistry. Although many patients had liver biochemis-
try (ALT, AST and GGT) within the normal reference range,
there were highly significant correlations between IHCL and
serum levels of ALT (r=0.47), AST (r=0.49), and GGT
(r=0.50) (all p,0.05). There was no significant correlation
between IHCL and total cholesterol (r=0.16; p = 0.44), LDL-
cholesterol (r=0.11; p= 0.64) and triglycerides (r=0.12;
p = 0.58)), nor between IHL and total serum adiponectin
concentration (r=20.04; p = 0.88).
Body composition. There was no significant correlation
between IHL and any of the following: body mass index (r=0.16;
p = 0.44), total body weight (r=20.24; p = 0.25), total abdominal
body fat (r=20.04; p = 0.84), and abdominal visceral (r=0.01;
p = 0.96) and abdominal subcutaneous adipose tissue volume
(r=20.04; p = 0.86).
Changes in Metabolic Parameters, Weight and Body
Composition with GLP-1 RA (Table 1)
Body weight. Six months of treatment with GLP-1 RA
(either exenatide or liraglutide) was associated with a significant
median weight loss of 5 kg, a relative reduction of 4.3%.
Biochemistry. Treatment was associated with significant
median reductions in HbA1c of 1.6%, in ALT from 40 (31,44)
to 31 (27,43) U/L and GGT from 69 (34,100) to 43 (22, 69)
U/L. Serum total adiponectin concentration increased signifi-
cantly in all subjects (p,0.00005). However, a lack of significant
correlation between adiponectin increase and any measure of
body composition is consistent with previous reports [33].
Body composition. There were significant reductions in
abdominal VAT and SAT and in IHL. The median relative
reduction in IHL was 42%, 4% in total body weight and 7–
11% in abdominal SAT or VAT; IMCL did not change.
Variables Associated with Reduction in Hepatic Steatosis
Biochemical response. The reduction in IHL with treat-
ment was accompanied by a significant reduction in ALT
(p,0.05) and GGT (p,0.001) but not in AST (p= 0.1). There
was a significant correlation between relative IHL reduction and
relative reduction in HbA1c percentage (r=0.49,p = 0.01); the
correlation between absolute changes fell just short of statistical
significance (r=0.38,p = 0.06), not surprisingly given the wide
range of starting values of IHL, and the strong relationship
between the starting IHL and the absolute reduction in IHL (see
below). There was no significant correlation between the absolute
GLP-1 Receptor Agonists and Hepatic Steatosis
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changes in total adiponectin concentration and IHL (r=20?19,
p = 0?43) (Figure 1).
Weight loss. There was no significant relationship overall
between the relative or absolute amount of weight loss and the
reduction in IHCL (Figure 2). Reinforcing this, when we sub-
divided patients into two groups according to amount of weight
loss (patients with #5% weight loss (n = 15) and patients with
$5% weight loss (n = 10), the change in IHCL was not
significantly different between the two groups (p = 0.35)
(Figure 3): there was an absolute reduction in IHL of 15.7%
(95% CI: 8.2, 23.2) for patients with #5% weight loss (mean
weight change, 2.6 (1.5,3.5) kg) versus an absolute reduction in
IHL of 10?7% (95% CI 2.7, 18.8) for patients with weight loss
of .5% (mean weight change, 8.6 (7,10.3) kg).
Abdominal adipose tissue and muscle lipid. (Figure 2)
There was no correlation between the reduction in IHCL and the
reduction in total abdominal fat (r=20?02; p = 0?93), VAT
(r=0?04; p= 0?85), SAT (r=20.13; p = 0?55) or with IMCL in
either soleus or tibialis anterior (r=20?17, p = 0?44; r=0?17,
p = 0?45 respectively).
Baseline intrahepatic lipid. (Figure 3) The most striking
correlation was seen between the pre-treatment IHL and the size
of the reduction in IHL, such that those individuals with the
highest pre-treatment IHL had the greatest absolute reduction in
IHL with treatment (r = -0?70; p = 0?0001).
Discussion
This study demonstrates that 6 months of GLP-1 RA treatment
(with exenatide or liraglutide) in patients with T2DM dramatically
improves hepatic steatosis. The individual changes in IHL did not
correlate with changes in total body weight, and total abdominal
fat, VAT or SAT, but it did correlate with reduction in HbA1c. A
recent randomised parallel-group open-label trial (LEAD-6)
reported similar weight loss, but significantly greater reductions
in HbA1c, using once-daily liraglutide compared with twice daily
exenatide [34]. However, we did not observe any differences in
these variables between the two agents, albeit using small group
sizes.
An obvious question arises from our results: to what extent is
reduction in liver fat, mediated by GLP-1 RAs, explained by
weight loss? Lifestyle intervention studies have found that modest
(5–8%) weight loss has a significant effect on hepatic steatosis in
patients with T2DM [21]. Furthermore, Lim et al, demonstrate
that with a 15% reduction in body weight, with eight weeks of a





Median Relative change %
(Interquartile range) p value
Clinical characteristics
Body weight (kg) 116.7 (102.4 to 125.3) 111.3 (98.3 to 118.7) 25 (26.5, 23.5) 24.3 (26.4 to 21.8) ,0.00005
BMI (kg/m2) 38.4 (5.6) 36.7 (5) 21.7 (22.2, 21.2) 24.5 (26.4 to 21.9) ,0.00005
Waist circumference (cm) 125 (111 to 132) 120 (107 to 128) 25.2 (27.4, 22.9) 23.2 (27.9 to 21.1) 0.0001
Fat (L) 21 (5.1) 19.3 (4.8) 21.8 (22.5, 21.1) 27.5 (211.7 to 0.3) ,0.00005
Systolic BP (mmHg) 133 (120 to 145) 125 (120 to 138) – 26.1 (211.3 to 0) 0.0151
Diastolic BP (mmHg) 84 (78 to 89) 80 (75 to 84) – 25.9 (210.5 to 0) 0.0062
Biochemical and metabolic
FPG (mmol/l) 10.8 (8.9 to 14) 8.3 (6 to 10.1) – – 0.0007
HbA1c (%) 9.6 (7.9 to 10.7) 7.5 (6.5 to 8.5) 21.6 (22.4, 20.8) – 0.0003
AST (U/ml) 27 (20 to 38) 25 (21 to 33) – – 0.0998
ALT (U/ml) 40 (31 to 44) 31 (27 to 43) – – 0.0118
GGT (U/ml) 69 (34 to 100) 43 (22 to 69) – – 0.0004
Total cholesterol (mmol/l) 4.3 (3.6 to 4.9) 4 (3.5 to 5.1) – – 0.6183
HDL (mmol/l) 1 (0.9 to 1.3) 1 (1 to 1.2) 0 (0, 0.1) – 0.1749
LDL (mmol/l) 2 (1.6 to 2.4) 2.1 (1.6 to 2.7) – – 0.423
Trig (mmol/l) 2.1 (1.7 to 3.7) 2 (1.5 to 2.7) – – 0.0713
Total Adiponectin (mg/ml) 2.51 (1.92 to 5.65) 3.50 (2.00 to 7.79) 0.87 (0.53, 1.21) – ,0.00005
Adipose Tissue volumes
Abdominal VAT (L) 7.2 (2.6) 6.3 (2.1) – 211.2 (215.4 to 22.1) 0.0007
Abdominal SAT (L) 13.9 (4.2) 12.9 (4.1) 20.9 (21.3, 20.6) 26.8 (212 to 0.2) ,0.00005
VAT:SAT ratio 0.5 (0.4 to 0.8) 0.5 (0.4 to 0.7) – 0.0386
MR Spectroscopy (1H MRS)
Liver fat (% CH2/water) 28 (17 to 43) 21 (7 to 29) 218 (219, 29) 242 (259 to 217) ,0.00005
Soleus IMCL (CH2/creatine) 19 (10 to 25) 17 (10.1 to 22) – 25 (231 to 46) 0.4937
Tibialis Anterior IMCL (CH2/creatine) 15 (11 to 25) 13 (9 to 21) – 0 (238 to 38) 0.8671
*Used natural log of variable pre & post; change is the ratio (post to pre) of geometric means with 95% confidence interval. **Used Wilcoxon matched-pairs. Mean 6
standard deviation, median (lower quartile to upper quartile), mean difference (lower 95% confidence limit, upper 95% confidence limit).
doi:10.1371/journal.pone.0050117.t001
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dietary intervention consisting of a 600 kcal diet, liver fat reduced
by a total of 7065% [35]. However, there has been relatively little
work on the effects of GLP-1 RAs on liver fat to address this
question. In a single case report, in which 44 weeks of exenatide
was associated with a similar reduction in body weight as we
observed, a 4 kg absolute reduction or a 5% relative reduction, 1H
MRS-measured IHCL declined by 73% (from 16% to 4%) [27].
Furthermore, in an uncontrolled study of 8 patients with T2DM
and biopsy-proven NAFLD, which examined the effects of 28
weeks exenatide using biopsies pre- and post-treatment, with
similar weight loss to that observed in our study (mean weight loss
of 4.9 kg), steatosis reduced significantly in half of the patients
[28].
In contrast, several reports highlight the differential effects of
GLP-1 RAs, and other pharmacological treatments for T2DM, on
body composition and IHL. Belfort et al examined the effects of 6
months treatment with pioglitazone in 55 patients with either
impaired glucose tolerance or T2DM. Treatment was associated
with a 54% reduction in 1H MRS-measured IHL despite marginal
weight gain [25]. The results of other, uncontrolled, studies of
glitazone therapy in T2DM demonstrate consistent reductions of
,50% in liver fat, despite an absence of weight loss or even weight
gain, although none have taken paired biopsies to examined for
changes in other histological features [23,36]. In a recent study of
21 patients with T2DM a combination of exenatide with
pioglitazone was associated with a greater reduction in 1H
MRS-measured IHCL than pioglitazone alone (61% vs. 41%),
despite there being no overall change in body weight using this
pharmalogical combination and weight gain with pioglitazone
alone [37]. Likewise, Taikinnen et al. demonstrated reductions in
hepatic fat with rosiglitazone independent of changes in VAT or
SAT [23]. Indeed, in the present study we found no significant
relationship between changes in IHL and changes in body weight
or any component of fat mass.
There are other potential mechanisms by which GLP-1 RAs
may work, perhaps independently of weight loss. GLP-1 RAs may
act directly on the hepatocytes. Transgenic rats deficient in
dipeptidyl peptidase-4 (DPP4-), the enzyme that degrades endog-
enous GLP-1, have a threefold higher basal active GLP-1; they not
only have lower hepatic fat, but are also protected against hepatic
Figure 1. Upper: Relative changes in liver fat related to relative change in HbA1c (r=0.49; p=0.01) (left) and absolute change in liver
fat related to absolute change in HbA1c (r=0.38; p=0.06) (right). Lower: Relative changes in liver fat related to relative change in weight
(r=0.21; p = 0.31) (left) and absolute change in liver fat related to absolute change in weight (r=20.04; p = 0.86) (right).
doi:10.1371/journal.pone.0050117.g001
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steatosis when fed a high-fat diet [8]. This reduced hepatic fat is
mediated by down-regulation of transcription factors for enzymes
involved in hepatic lipogenesis and up-regulation of carnitine
palmitoyltransferase-1 (CPT1), a key regulator of fatty acid
oxidation. Furthermore, in vitro studies suggest that the direct
action of GLP-1 on hepatic steatosis is mediated by activation of
key metabolic signalling pathways, including the AMP-activated
protein kinase (AMPK) pathway and the insulin signalling
pathway [8,10,11], which would be associated with increased
hepatic fatty acid oxidation and hence improved insulin sensitivity.
The recent identification of GLP1 receptors (GLP1-R) in human
liver makes this mechanism a possibility [10]. There have been no
randomised controlled studies using GLP-1 RA with paired liver
biopsies, for an appropriate time frame, to determine the effects of
the GLP-1 RAs on hepatic signalling or metabolic pathways.
The significant increase in serum total adiponectin concentra-
tion with GLP-1 RA therapy, consistent with previous data
[17,19], maybe implicated in the mechanism by which liver fat is
reduced. However, we did not observe any significant relationship
between plasma adiponectin concentration and IHCL, in contrast
to a weak correlation (r =20.219) previously observed in 114
subjects with NAFLD [19].
A further possibility, consistent with the correlation we observed
between effects on IHL and HBA1c, is that the effects on IHL are
secondary to improved glucose tolerance, with reduced hyperin-
sulinemia (and perhaps reduced hyperglycaemia), reducing the
increased rate of hepatocyte lipogenesis characteristic of these
patients [13]. The close correlation between changes in IHL and
glycaemic control, in absence of changes in other measures of
body composition, highlights the key regulatory role of the liver in
metabolic control in overweight/obese patients.
Whatever the cause of the change in IHL, the correlation
between the pre-treatment IHL and the size of the reduction in
IHL is striking (Fig 3): put differently, the fractional change is less
variable between patients than the absolute change. It is
impossible to exclude the possibility that part of this relationship
is due to the purely statistical phenomenon of regression to the
mean, but it arguably makes metabolic-control sense that
alterations in either downstream or upstream enzymes of fat
metabolism should have effects proportional to triglyceride pool
size.
It is not clear what effect the reduction in liver fat had on whole
body or hepatic insulin resistance in these subjects. Rates of fasting
hepatic glucose production (HGP) and insulin sensitivity of liver
(assessed by measuring rate of suppression of HGP by insulin) can
be determining using [6,6-2H2] glucose and a hyperinsulinemic,
euglycemic clamp [21]. More recently, Hattersley et al. validated a
simple index of hepatic insulin resistance using serum glucose and
insulin against the gold standard methods using stable isotopes and
clamps [38]. For technical reasons, serum insulin concentrations
could not be measured in the current study, thus we could not
make us of this potentially important physiological measure.
The methodology in this study does not allow us to scrutinize
the effects on hepatic inflammation or fibrosis. A longer duration
study is warranted with examination of changes in intracellular
signaling pathways to assess potential direct mechanisms of action
on hepatic lipogenesis and in histopathological changes pre-and
post-therapy to address progression through the NAFLD spec-
trum, including measures of inflammation and fibrosis. Similarly,
it is unclear whether these drugs can impact upon the liver-related
and cardiovascular burden of NAFLD in these high-risk T2DM
patients.
T2DM patients with NAFLD have been suggested as a
population worthy of further clinical study to examine the role
of insulin sensitizers and related drugs in ameliorating NAFLD
[22]. The present findings are thus of potential clinical relevance,
and although the present study involves a relatively small sample
size and an observational design without use of control subjects, it
suggests that these drugs may have a therapeutic benefit,
Figure 2. Correlation between changes in liver fat (%) and:
Upper: change in total abdominal fat (litres). Middle: change in
abdominal subcutaneous fat (litres). Lower: change in intra-abdominal
visceral fat (litres).
doi:10.1371/journal.pone.0050117.g002
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potentially even in lean patients. The literature lacks adequately
powered, randomised, placebo-controlled intervention studies
using GLP-1 analogues in patients with NAFLD, with or without
T2DM, to demonstrate the inter-relationship between the
biochemical, metabolic and histological responses. The results of
this study should be of use to power a larger, more definitive study
incorporating appropriate control groups. This might include a
patient group treated with an agent that improves only glycaemic
control but not weight (e.g. subcutaneous insulin) and a second
group in whom weight loss alone is achieved (e.g. through dietary
intervention) to determine the independent contributions of
improvements in weight and in glycaemic control. The findings
from the present study suggest that the results of such clinical trials
using GLP-1 RAs to treat NAFLD might be of considerable
therapeutic interest.
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